RVNC - Revance Therapeutics EPS misses by $0.30 beats on revenue; updates FY20 outlook
Revance Therapeutics (RVNC): Q3 GAAP EPS of -$1.34 misses by $0.30.Revenue of $3.8M (+7500.0% Y/Y) beats by $2.09M.FY20 guidance: GAAP operating expense of $285M-295M; non-GAAP operating expense of $220M-230M; non-GAAP research and development expense of $95M-100M.Shares -5.8%.Press Release
For further details see:
Revance Therapeutics EPS misses by $0.30, beats on revenue; updates FY20 outlook